• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

    10/22/25 6:17:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care
    Get the next $STAA alert in real time by email

    Cautions Board Against Taking Any Substantive or Procedural Action on Alcon Transaction or Delaying Shareholder Vote

    Calls for Board Refresh to Rebuild Shareholder Trust After Deeply Flawed Sales Process

    Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which owns 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), notified the Company's Board of Directors (the "Board") yesterday that it intends to call a Special Meeting of STAAR shareholders for the purpose of removing several directors.

    Neal C. Bradsher, Broadwood Founder and President, said:

    "We informed the Board yesterday of our intention to call a Special Meeting of shareholders for the purpose of removing several directors in light of the overwhelming opposition to the proposed acquisition of STAAR by Alcon.

    We once again caution the Board against taking any steps to delay a vote on the proposed transaction or making any last-minute changes to the transaction without substantial input from and alignment with shareholders.

    It is clear to us that the Board no longer has the confidence of shareholders, and that new directors are needed to properly steward the Company and restore shareholder trust.

    We anticipate that a refreshed Board would consider, among other matters, how to run a full, fair, independent, and open strategic alternatives process to maximize value that is untainted by the process issues and conflicts of interest that afflicted this proposed transaction with Alcon."

    Broadwood encourages its fellow shareholders to review its materials at www.LetSTAARShine.com and to vote on the GREEN Proxy Card "AGAINST" the proposed acquisition of STAAR by Alcon Inc.

    About Broadwood

    Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal C. Bradsher is the President of Broadwood Capital.

    Certain Information Concerning the Participants

    Special Meeting of Shareholders Scheduled for October 23, 2025

    Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of STAAR in connection with the special meeting of shareholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the "Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Special Meeting. SHAREHOLDERS OF STAAR ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of STAAR's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Special Meeting of Shareholders to Remove Members of the Board

    The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the "Shareholder Meeting"). The Shareholder Meeting will be separate, distinct and unrelated to the Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants' ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

    Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on October 22, 2025 and is available here.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251022937035/en/

    Investor Contacts

    John Ferguson / Joseph Mills

    Saratoga Proxy Consulting LLC

    [email protected]

    [email protected]

    (212) 257-1311

    (888) 368-0379

    Media Contacts

    Scott Deveau / Jeremy Jacobs

    August Strategic Communications

    [email protected]

    (323) 892-5562

    Get the next $STAA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STAA

    DatePrice TargetRatingAnalyst
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    6/11/2024$46.00Neutral → Buy
    BTIG Research
    3/11/2024$30.00 → $50.00Hold → Buy
    Stifel
    More analyst ratings

    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jiang Wei converted options into 20,967 shares, increasing direct ownership by 592% to 24,510 units (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    8/13/25 6:39:57 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by CFO Andrews Deborah J

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:31:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Zhou Lilian Yansheng

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    6/26/25 6:29:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that STAAR and Alcon have agreed to adjourn STAAR's Special Meeting of Stockholders (the "Special Meeting") scheduled for October 23, 2025, in connection with STAAR's merger agreement with Alcon. No other business will be conducted at the Special Meeting. STAAR is adjourning the Special Meeting until 8:30 a.m. Pacific Time on November 6, 2025. The record date for STAAR stockholders eligible to vote at the Special Meeting remains the close of business on September 12, 2025. Stoc

    10/23/25 12:09:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

    Cautions Board Against Taking Any Substantive or Procedural Action on Alcon Transaction or Delaying Shareholder Vote Calls for Board Refresh to Rebuild Shareholder Trust After Deeply Flawed Sales Process Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which owns 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), notified the Company's Board of Directors (the "Board") yesterday that it intends to call a Special Meeting of STAAR shareholders for the purpose of removing several directors. Neal C. Bradsher, Broadwood Founder and President, said: "We informed the Board yesterday of our intention to call a Special M

    10/22/25 6:17:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction

    Shareholders Have the Information They Need to Make an Informed Vote Preliminary Net Sales Results for Third Quarter Underscore a Positive Trajectory Continues to Oppose the Proposed Merger and Will Vote AGAINST at the Special Meeting Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today issued the following letter to the Board of Directors of STAAR regarding Yunqi's opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. The text of the letter to the Board is as follows:

    10/20/25 5:32:00 PM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on STAAR Surgical with a new price target

    Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

    4/21/25 8:38:55 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Jefferies

    Jefferies downgraded STAAR Surgical from Buy to Hold

    2/12/25 11:13:24 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical downgraded by Mizuho with a new price target

    Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously

    2/12/25 7:11:03 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/10/25 7:00:22 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/7/25 8:28:12 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

    4 - STAAR SURGICAL CO (0000718937) (Issuer)

    4/2/25 8:33:34 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    SEC Filings

    View All

    SEC Form DEFA14A filed by STAAR Surgical Company

    DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)

    10/23/25 4:23:05 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by STAAR Surgical Company

    8-K - STAAR SURGICAL CO (0000718937) (Filer)

    10/23/25 4:21:11 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form DFAN14A filed by STAAR Surgical Company

    DFAN14A - STAAR SURGICAL CO (0000718937) (Subject)

    10/20/25 5:00:03 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Financials

    Live finance-specific insights

    View All

    STAAR Surgical Reports Second Quarter 2025 Results

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

    8/6/25 4:01:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    Alcon Agrees to Acquire STAAR Surgical

    STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

    8/5/25 1:01:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025

    STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

    7/31/25 10:03:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Leadership Updates

    Live Leadership Updates

    View All

    STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has

    6/25/25 9:28:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Announces Leadership Transition

    Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

    2/26/25 4:45:00 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

    New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:

    5/1/24 7:00:00 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    9/6/24 9:51:09 AM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    2/13/24 5:14:04 PM ET
    $STAA
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

    SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

    1/26/24 9:19:42 AM ET
    $STAA
    Ophthalmic Goods
    Health Care